Merge eClinical Announces New Mobile App
Study Connect™ App Enables the Mobile Management of Randomization, Inventory Management and Unblinding in Clinical Trials
Study Connect™, a new mobile app from Merge eClinical, allow users of its eClinicalOS (eCOS) to perform a wide array of clinical trial management functions from their iOS-based mobile devices.
Seamlessly integrated with eCOS, Study Connect™enables researchers to:
· Manage randomization of subjects
· Coordinate dispensing and inventory management
· Unblind individual subjects, as circumstances warrant
· Stay connected with real-time customized notifications
· Monitor enrollment and establish milestone alerts
· Share top-level statistics for each study with key stakeholders using the study dashboard
· Expedite approval response times for critical study decisions such as patient study eligibility
· Maintain security with the ability to set customized role-based permissions for individual studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
